Investigating how a specific enzyme affects blood vessel health in atherosclerosis
Nicotinamide nucleotide transhydrogenase regulates redox balance in atherosclerosis
This study is looking at how a protein called NNT helps keep blood vessels healthy by controlling harmful substances that can cause heart problems, especially in people with atherosclerosis, and it hopes to find new ways to treat this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Augusta University NIH-funded |
| Lab location | 1 site (Augusta, United States) |
| Project ID | NIH-10807985 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of nicotinamide nucleotide transhydrogenase (NNT) in maintaining the balance of reactive oxygen species in blood vessels affected by atherosclerosis. By examining how reduced levels of NNT in endothelial cells contribute to inflammation and plaque formation, the study aims to uncover potential therapeutic targets. The approach includes using advanced techniques like CRISPR to manipulate NNT levels in human cells and animal models, providing insights into the underlying mechanisms of atherosclerosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with atherosclerosis or those at high risk for developing cardiovascular diseases.
Not a fit: Patients without atherosclerosis or those with unrelated cardiovascular conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve vascular health and reduce the risk of cardiovascular diseases associated with atherosclerosis.
How similar studies have performed: Previous research has shown promising results in targeting oxidative stress in cardiovascular diseases, suggesting that this approach may yield significant insights.
Where this research is happening
Augusta, United States
- Augusta University — Augusta, United States (Active)
Researchers
- Principal investigator: Krzywanski, David M — Augusta University
- Study coordinator: Krzywanski, David M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.